Carebook Technologies (CRBK) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue grew 37% year-over-year to $3.7M, driven by expansion in employer health and wellness, pharmacy solutions, and large client implementations.

• Annual recurring revenue reached $12.1M as of June 30, 2024, up 14% year-over-year, with 63% from clients outside Canada.

• Adjusted EBITDA loss improved to $(0.1)M, with margin improving to (3)% from (9)% in Q2 2023.

• Loss from operations improved to $(0.5)M from $(0.7)M year-over-year, and net loss remained stable at $(0.7)M.

• User base expanded to 4.6M across combined platforms.

Financial highlights

• Q2 2024 revenue was $3.7M, up from $2.7M in Q2 2023, with 65% from the employer vertical and 35% from pharmacy.

• Adjusted EBITDA improved from $(0.2)M in Q2 2023 to $(0.1)M in Q2 2024.

• Loss from operations improved by $0.2M, from $(0.7)M to $(0.5)M year-over-year.

• Net loss held steady at $(0.7)M compared to the same quarter last year.

• ARR increased 14% to $12.1M as of June 30, 2024.

Outlook and guidance

• Management targets Adjusted EBITDA breakeven or better in 2024, with a positive financial outlook and continued organic revenue growth.

• Focus remains on cost management, margin improvement, and disciplined pursuit of accretive acquisitions and partnerships.

• Pharmacy revenue expected to remain stable in 2024 but may decline thereafter.

• Company sees future M&A opportunities in a fragmented wellness market.

• Management expects organic revenue growth to continue, though at a slower pace in coming quarters.